News

A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and diabetes had a significant improvement in symptoms when taking semaglutide.

Saint Luke’s Mid America Heart Institute today announced results from the STEP HFpEF DM trial.

During Heart Month, we are talking about the risks of undiagnosed heart failure and treatment options for those with heart failure.

FOX4 talked to Ted Perez and his heart transplant surgeon, Dr. Russ Davis, about the lifelong Chiefs fan's incredible story.

Saint Luke’s Mid America Heart Institute was the first in Kansas and Missouri, and one of only 27 US institutions, to participate in PULSED AF clinical trial.

We’re talking about how mental health can play a big role in setting yourself up for success when it comes to making healthy lifestyle changes.

A man from Columbia, Missouri, got a new heart and a second chance at life, marking the 1,000th heart transplant at Saint Luke's Mid America Heart Institute.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.